Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Urothelial Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Bladder Cancer (180
)
Bladder Cancer (180
)
›
Associations
(452)
News
Trials
Search handles
@AdityaBagrodia
@AldoLADETTINO
@AndreaNecchi
@ArndtVogel
@BourlonMaite
@BraunMDPhD
@CParkMD
@ChristianRolfo
@ClarkHenegan
@CyclingDoctor
@DrChoueiri
@DrDanielHeng
@DrFelixGuerrero
@DrRanaMcKay
@DrScottTagawa
@DrTylerStewart
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_RaviMadan
@DrewMoghanaki
@ERPlimackMD
@EladSharonMD
@FaltasLab
@FuenteApolo
@GGiannarini
@GIcancerDoc
@GustavoVillold4
@JoshMeeks
@KeithKow
@KidneyCancerDoc
@KonradStawiski
@KrisWentzelMD
@Latinamd
@LauraBukavinaMD
@LoebStacy
@LuisCB_MedPharm
@LujanPomponio
@MPishvaian
@Martin_AngelMD
@MattGalsky
@NagiSaghir
@NazliDizman
@NicholasZaorsky
@NicoleKuderer
@NormandBlais
@OncHahn
@OncoBellmunt
@OncoLucus
@OncoRod
@PBlanchardMD
@PGrivasMDPhD
@PLMcCarthyMD
@ParamMariappan
@PaulSargos
@PauloBergerot
@PavlosMsaouel
@PrimoLaraMD
@ProfSyedHussain
@Prof_Nick_James
@RPachynski
@RandySweisMD
@RicBertolo
@RohanGarjeMD
@SWilliams_MD
@SoaresAndrey
@StoverLab
@TapiaJC1
@TiansterZhang
@TomFlaigMD
@TylerSbrt
@UroDocAsh
@VamsiVelcheti
@VedangMurthy
@ViktorGruenwald
@VivekSubbiah
@VoglNY
@WesKassouf
@ZilliThomas
@_ShankarSiva
@aadel_chaudhuri
@achoud72
@alantanmd
@alirezaghoreifi
@alshamsi2000
@amerseburger
@anandoncologist
@apolo_andrea
@arkhaki
@bergsa83
@brian_rini
@cczielinski
@cdanicas
@chulkimMD
@daviesbj
@dawood_findakly
@docjavip
@docpriyamvada
@dralvaropinto
@drenriquegrande
@drgandara
@drlw2309
@duemed
@fmassari79
@g_develasco
@gbanna74
@jamecancerdoc
@jasonlukemd
@jeffyoriomd
@jesusanampa
@jgong15
@joanfundi
@jsoriamd
@kmody29
@koshkin85
@malvarezmaestro
@montypal
@mtmdphd
@mtsiatas
@naborala
@nataliagandur
@navstruck
@neerajaiims
@oalhalabimd
@outliersbio
@pcvblack
@pekijammer
@rschilsky
@sgilbert1973
@shilpaonc
@sonpavde
@tmprowell
@tompowles1
@weldeiry
@weoncologists
Search handles
@AdityaBagrodia
@AldoLADETTINO
@AndreaNecchi
@ArndtVogel
@BourlonMaite
@BraunMDPhD
@CParkMD
@ChristianRolfo
@ClarkHenegan
@CyclingDoctor
@DrChoueiri
@DrDanielHeng
@DrFelixGuerrero
@DrRanaMcKay
@DrScottTagawa
@DrTylerStewart
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_RaviMadan
@DrewMoghanaki
@ERPlimackMD
@EladSharonMD
@FaltasLab
@FuenteApolo
@GGiannarini
@GIcancerDoc
@GustavoVillold4
@JoshMeeks
@KeithKow
@KidneyCancerDoc
@KonradStawiski
@KrisWentzelMD
@Latinamd
@LauraBukavinaMD
@LoebStacy
@LuisCB_MedPharm
@LujanPomponio
@MPishvaian
@Martin_AngelMD
@MattGalsky
@NagiSaghir
@NazliDizman
@NicholasZaorsky
@NicoleKuderer
@NormandBlais
@OncHahn
@OncoBellmunt
@OncoLucus
@OncoRod
@PBlanchardMD
@PGrivasMDPhD
@PLMcCarthyMD
@ParamMariappan
@PaulSargos
@PauloBergerot
@PavlosMsaouel
@PrimoLaraMD
@ProfSyedHussain
@Prof_Nick_James
@RPachynski
@RandySweisMD
@RicBertolo
@RohanGarjeMD
@SWilliams_MD
@SoaresAndrey
@StoverLab
@TapiaJC1
@TiansterZhang
@TomFlaigMD
@TylerSbrt
@UroDocAsh
@VamsiVelcheti
@VedangMurthy
@ViktorGruenwald
@VivekSubbiah
@VoglNY
@WesKassouf
@ZilliThomas
@_ShankarSiva
@aadel_chaudhuri
@achoud72
@alantanmd
@alirezaghoreifi
@alshamsi2000
@amerseburger
@anandoncologist
@apolo_andrea
@arkhaki
@bergsa83
@brian_rini
@cczielinski
@cdanicas
@chulkimMD
@daviesbj
@dawood_findakly
@docjavip
@docpriyamvada
@dralvaropinto
@drenriquegrande
@drgandara
@drlw2309
@duemed
@fmassari79
@g_develasco
@gbanna74
@jamecancerdoc
@jasonlukemd
@jeffyoriomd
@jesusanampa
@jgong15
@joanfundi
@jsoriamd
@kmody29
@koshkin85
@malvarezmaestro
@montypal
@mtmdphd
@mtsiatas
@naborala
@nataliagandur
@navstruck
@neerajaiims
@oalhalabimd
@outliersbio
@pcvblack
@pekijammer
@rschilsky
@sgilbert1973
@shilpaonc
@sonpavde
@tmprowell
@tompowles1
@weldeiry
@weoncologists
Filter by
Latest
8ms
Tell me about ATM alterations for the treatment of bladder cancer please. (@ClemensLaseur)
8 months ago
ATM (ATM serine/threonine kinase)
8ms
We reported in 2021 p21 & Rb truncating mutations in kidney chromophobe renal cell carcinomas with suspected implications for therapy & pathogenesis. I’m fascinated by p21 & Rb truncating mutations in bladder tumors as well. More research is needed. https://t.co/RrwEr4G0Tv (@weldeiry)
8 months ago
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
8ms
Thrilled to share the stage with @LauraBukavinaMD at #BCANTT23! I'll be delving into 'PPARG the Rogue Conductor's Broken Harmony: How MAPK Pathway Alterations Drive Bladder Cancer Progression,' a new paradigm in bladder cancer. Looking forward to an exciting exchange of ideas! (@RaieBekele)
8 months ago
PPARG (Peroxisome Proliferator Activated Receptor Gamma)
8ms
From science to clinical utility: @Cxbladder Detect - #BladderCancer detection for patients who present with hematuria. Tamer Aboushwareb, MD, PhD @PacificEdgeLtd, Neal Shore, MD, FACS @AtlanticUrology & @JoshMeeks @NM_Urology join to discuss on UroToday > https://t.co/ntpVmbLok6 (@urotoday)
8 months ago
Clinical
|
Cxbladder
8ms
Results from the phase 1b/2 #FIDES02 study: Derazantinib for metastatic #BladderCancer with activating FGFR1/2/3 genetic aberrations. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/7XkvtuwvBN (@urotoday)
8 months ago
Metastases
|
FGFR1 (Fibroblast growth factor receptor 1)
|
derazantinib (ARQ 087)
8ms
Insightful discussion with @y_loriot on the randomized #THOR study data that he presented at #ASCO23, confirming efficacy of Erdafitinib in FGFR3-altered platinum-refractory patients with #BladderCancer @ASCO @BladderCancerUS @IBCG_BladderCA @onclive @Uromigos (@koshkin85)
8 months ago
Clinical
|
FGFR3 (Fibroblast growth factor receptor 3)
|
Balversa (erdafitinib)
8ms
Outcomes with immune checkpoint inhibitors in patients with MTAP alterations in advanced #UrothelialCarcinoma. @rafee_talukder @fredhutch joins @PGrivasMDPhD @UW to discuss the effects of MTAP loss on survival rates on UroToday > https://t.co/h0RckbxsCz (@urotoday)
8 months ago
Clinical • Checkpoint inhibition • Metastases
|
MTAP (Methylthioadenosine Phosphorylase)
8ms
WATCH: @shilpaonc, of @ClevelandClinic, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in metastatic urothelial carcinoma & highlights next steps for frontline enfortumab vedotin & pembrolizumab in the phase 3 EV-302 trial. #oncology https://t.co/oZoRVYR0cX (@OncLive)
8 months ago
Metastases
|
Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
8ms
Great to sit down recently with the brilliant @apolo_andrea at ANZUP to discuss her perspective on biomarkers in bladder cancer, and promising future treatment strategies https://t.co/LHck0oQ3wj (@WeickhardtOnc)
8 months ago
8ms
Clinical perspective on recurrence mechanisms of non-muscle Invasive #BladderCancer. Join @jteoh_hk @CUHKMedicine and @UroDocAsh @MDAndersonNews as they discuss 5 key mechanisms driving recurrence. Learn more about tackling this challenging cancer here > https://t.co/lBb3VccLTr (@urotoday)
8 months ago
Clinical
8ms
Calling all Urology HCPs - if you're interested in Bladder Cancer Surgery and education, please sign up for free below: 👉 Sign up here : https://t.co/2CK0moivgC 🗓️ 21st & 22nd September 📍 Western General Hospital, Edinburgh @ParamMariappan @KARLSTORZUK @PhotocureASA (@medacPharmaUK)
8 months ago
Clinical • Surgery
8ms
Are there predictive #biomarkers of radiation therapy response in bladder cancer? 🎙️I chat w/ Prof. Ananya Choudoury @achoud72 @TheChristie on the latest research towards personalised care in bladder cancer radiation therapy #ANZUP23 @ANZUPtrials 👉 https://t.co/1ravkqLGDs (@lewisjwau)
8 months ago
8ms
Is there benefit to extended node dissection at time of radical cystectomy for metastatic #bladdercancer? How about excess toxicity? @koshkin85 of @UCSFCancer and Dr. Seth Lerner of @bcmhouston weigh in on SWOG S1011... https://t.co/cwAVU4Di1I (@GUOncologyNow)
8 months ago
Metastases
8ms
Join us on 8/15 for the next HSCO Symposium on #Bladder #Cancer featuring keynote speaker @mouwlab. Stay ahead on the latest updates on novel systemic agents, innovative combined treatments with surgery & radiation & more! Register at: https://t.co/GFGgdHZFtZ (@OSSatACCC)
8 months ago
Surgery
8ms
Predictive and prognostic role of the neutrophil-to-lymphocyte ratio in muscle invasive #BladderCancer treated with neoadjuvant chemotherapy and radical cystectomy. #BeyondTheAbstract with @mvdeimling, @VMS78880496, and @DrShariat > https://t.co/3WVW6evm8Q (@urotoday)
8 months ago
Clinical
8ms
#ReadNow A fascinating study on the effect of genomic subtypes of #UrothelialCarcinoma on response to immune checkpoint inhibitors. 🧬💉 Check out this expert commentary from @FaltasLab @WCMEnglanderIPM for all the insights! 📚 @JCO_ASCO @MichalSarfaty > https://t.co/D73U4u6i28 (@urotoday)
8 months ago
Checkpoint inhibition
8ms
#AgentOrange and #BladderCancer: Insights from a study on 25 million #Veterans. @SWilliams_MD @UTMBUrology and @UroCancerMD @VUMCurology highlight a retrospective cohort study looking at Agent Orange exposure and bladder cancer incidence > https://t.co/HvMTv16a4r (@urotoday)
8 months ago
Retrospective data
8ms
Extended follow-up results of the #CheckMate274 trial. @MattGalsky @TischCancer & @UroCancerMD @VUMCurology discuss the long-term results showing continued DFS benefits of adjuvant nivolumab vs PBO in high-risk muscle-invasive urothelial cancer patients > https://t.co/367pewfVsM (@urotoday)
8 months ago
Clinical
|
Opdivo (nivolumab)
8ms
VERY excitingly @BMJOncology have published our @BladderPath trial editorial!! 'Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath' #bladdercancer #data @Prof_Nick_James @mattsydes @CRCTU @MRCCTU https://t.co/EJ8HeERcq4 (@HattieMintz)
8 months ago
Clinical data
8ms
Join us today at 1pm ET/6pm GMT+1 to discuss the top advances of the year in #GuCancer with @QMBCI researchers @tompowles1, @drfrankiejs, and Dr. Matthew Young. Read the article here: https://t.co/WWL08K4IVs @ChrisSweens1 #ACSCancerChat #blcsm #kcsm #pcsm #KCRS23 (@JournalCancer)
8 months ago
8ms
🔘 Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer #bladdercancer @AACR https://t.co/m6KtQXHHYf (@drenriquegrande)
8 months ago
8ms
Hello everyone! Thanks for joining our discussion on the Top Advancements of the Year in GU cancers in 2022. I’m Frankie, a clinical trial doctor on @tompowles1 team currently undertaking my PhD in wearable devices and circulating biomarkers in bladder cancer💡 (@drfrankiejs)
8 months ago
Clinical
8ms
I’m going to hand over to @tompowles1 to talk about bladder cancer top advancements! #ACScancerchat @JournalCancer @BartsECMC (@drfrankiejs)
8 months ago
8ms
In patients with FGFR-mutant urothelial cancer (UC), after immune checkpoint progression, do you use enfortumab vedotin (EV) or erdafitinib ? #ACScancerchat https://t.co/F6nmlNDAh5 (@VivekSubbiah)
8 months ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
8ms
Would bipolar ERBT @LamideyNoury replace my favorite 😍 (Thulium-Yag) @samir__lamrini for Bladder tumors, New RCT🤔 & New challenges @KariTikkinen @StefaniaFerret @jteoh_hk @drkemalsarica @drmahmoudabdel @GoumasUrologia @fgomsan @DrParimalGharia @niteshkuro @DrShariat @urotoday (@Mohamedendourol)
8 months ago
8ms
📢Happy to share the Special Issue "Comprehensive Review on Upper Tract Urothelial Carcinoma: An Update in 2023" edited by Dr. @Hoomandjaladat and @alirezaghoreifi 📅Deadline for manuscript submissions: 31 December 2023. 🌈https://t.co/v2aNSo119J #mdpicancers via @Cancers_MDPI (@CS9VLzp6LyZeSdv)
8 months ago
Review
8ms
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD (@urotoday)
8 months ago
Metastases
|
Keytruda (pembrolizumab)
9ms
The association between FGFR3 alterations and response to platinum-based chemotherapy in locally advanced and metastatic #UrothelialCarcinoma. @IyerGopa @MSKCancerCenter joins @UroCancerMD @VUMCurology in this discussion on UroToday > https://t.co/k7xDR7cTdQ @EUplatinum (@urotoday)
9 months ago
Metastases
|
FGFR3 (Fibroblast growth factor receptor 3)
9ms
Last #ACSCancerChat question @drfrankiejs @tompowles1 & Dr. Young 🙏 What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan❓ @OncoAlert 🚨 @VivekSubbiah @WalterStadler5 (@weoncologists)
9 months ago
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
9ms
Exciting developments in urothelial cancer treatment! Enfortumab vedotin, sacituzumab govitecan, and derazantinib are showing promise. Looking forward to EV and pembrolizumab results in first-line and MIBC. SG vs. chemo in platinum refractory disease is generating buzz.… https://t.co/XrJPm7T3jG (@nataliagandur)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • derazantinib (ARQ 087)
9ms
Enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), have shown promising results in treating urothelial cancer. They have exhibited significant objective response rates and durable responses, particularly in patients who have previously received… https://t.co/gwK2m0W2M9 (@nataliagandur)
9 months ago
Clinical
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
9ms
In #BladderCancer, listen to patients and prioritize the quality of initial management. @UroDocAsh @MDAndersonNews discusses the importance of capturing #PatientVoices and patient-reported outcomes. #ReadNow on UroToday > https://t.co/g45bWUT8zV @IBCG_BladderCA @WorldBladderCan (@urotoday)
9 months ago
Clinical • Patient reported outcomes
9ms
Combining CG0070 adenovirus vector with immune checkpoint blockade: Promising results for BCG unresponsive #BladderCancer patients. @UrogerliMD @MoffittNews joins @UroDocAsh @MDAndersonNews discussing promising preliminary results on UroToday > https://t.co/tXAEe9h6FB (@urotoday)
9 months ago
Clinical • Checkpoint inhibition • Checkpoint block
|
cretostimogene grenadenorepvec (CG0070)
9ms
Another great podcast from @declangmurphy @RenuEapen @SimaPorten debating bladder-preserving treatment for muscle-invasise bladder cancer. I hope a discussion about small renal masses will follow🤞 (@amorgado4)
9 months ago
9ms
Our next #ACSCancerChat takes place tomorrow at 1pm ET/6pm GMT+1. @tompowles1, @drfrankiejs, and Dr. Matthew Young will discuss the top advances of the year in #GUCancer. Revisit their article here: https://t.co/WWL08K4IVs @ChrisSweens1 #blcsm #kcsm #pcsm #KCRS23 (@JournalCancer)
9 months ago
9ms
Updated data from cohort H of the KEYNOTE-869 trial showed that neoadjuvant enfortumab vedotin did not produce AEs delaying surgical resection in the majority of patients with MIBC. @TomFlaigMD @CUAnschutz @ASCO #ASCO23 #blcsm https://t.co/dg0H8W2kut (@OncLive)
9 months ago
Clinical
|
Padcev (enfortumab vedotin-ejfv)
9ms
@SimaPorten @UCSFUrology was at @ANZUPtrials ASM this week and dropped into GU Cast studio in Melbourne to chat about cystectomy for bladder cancer. How to save more bladders despite high-grade cancer? Cracking episode @RenuEapen @declangmurphy https://t.co/mcgVB7SpdL (@gu_onc)
9 months ago
9ms
Good point! Bladder cancer will be a good example. We will need to know the distribution of EV after IO in the adj (CM-274) and 1L (CM-901) setting. JB100 did not mention EV as a common subseq tx. Same could happen with Bezultifan in RCC. Q is there. A proper method is needed. (@TapiaJC1)
9 months ago
9ms
A breakthrough in #urothelial cancer treatment: enfortumab vedotin combination therapy - expert insights and impressive response rates. @DrRosenbergMSK @MSKCancerCenter and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/E8a2is197W (@urotoday)
9 months ago
Combination therapy
|
Padcev (enfortumab vedotin-ejfv)
9ms
Carboplatin vs cisplatin-based chemotherapy for lymph node-positive #BladderCancer. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work by von Deimling et al. in @EUplatinum > https://t.co/ntudb1LBtY @mvdeimling @LAUrology_NL (@urotoday)
9 months ago
cisplatin • carboplatin
9ms
Single-agent enfortumab vedotin in the neoadjuvant setting had substantial antitumor activity and a high event-free survival rate with a manageable toxicity profile in patients with cisplatin-ineligible MIBC. @TomFlaigMD @CUAnschutz @ASCO #ASCO23 #blcsm https://t.co/5dwPCTuvLK (@OncLive)
9 months ago
Clinical
|
Padcev (enfortumab vedotin-ejfv)
9ms
Pros and cons of organ-sparing cystectomy in #BladderCancer patients: balancing oncologic and functional outcomes. @ParamMariappan and Maria Carmen Mir join @UroDocAsh to debate on UroToday > https://t.co/lSiJ6h4TAv (@urotoday)
9 months ago
Clinical
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login